What does the aromatic ring number mean for drug design?

Expert Opinion on Drug Discovery

Volumn 9, Issue 9, 2014, Pages 995-1003

  Ward, Simon E ^a   Beswick, Paul ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Aromatic ring; Chemical space; Developability; Heteroaliphatic ring; Heteroaromatic ring; Lipophilicity; Solubility

Indexed keywords

AROMATIC COMPOUND; DACLATASVIR; ENDOTHELIN RECEPTOR ANTAGONIST; HETEROCYCLIC COMPOUND; JANUS KINASE INHIBITOR; AROMATIC HYDROCARBON; DRUG;

CHEMICAL STRUCTURE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SOLUBILITY; DRUG STRUCTURE; LIPOPHILICITY; MEDICINAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; CHEMISTRY; HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; HYDROCARBONS, AROMATIC; PHARMACEUTICAL PREPARATIONS;

EID: 84906346249     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.932346     Document Type: Review

References (32)

1. Ritchie TJ, MacDonald SJ. The impact of aromatic ring count on compound developability: are too many aromatic rings a liability in drug design? Drug Discov Today 2009;14(21-22):1011-20
2. Ritchie TJ, MacDonald SJ, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today 2011;16(3-4):164-71
3. Ritchie TJ, MacDonald SJ, Peace S, et al. The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others? Med Chem Comm 2012;3(9):1062-9
4. Meanwell N. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 2011;24:1420-56
5. Lovering F, Bikker J, Humblet C Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752
6. Leeson PD, St-Galley SA, Wenlock MC. Impact of ion class and time on oral drug molecular properties. Med Chem Comm 2011;2:91
7. Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis c virus ns5a replication complex inhibitors. J Med Chem 2014;57(5):1643-72
8. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3025
9. Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl 2003;42(11):1210-50 (Pubitemid 36410287)
10. Wheeler SE. Understanding substituent effects in noncovalent interactions involving aromatic rings. Acc Chem Res 2013;2013:46(4):1029-38
11. Kombarov R, Altieri AGenis D, et al. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery. Mol Divers 2010;14:193-200
12. DeSimone RW, Currie KS, Mitchell SA, et al. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen 2004;7:473-93 (Pubitemid 39108267)
13. Lee S, Raw AS, Yu L. Significance of drug substance physicochemical properties in regulatory quality by design. Drugs Pharm Sci 2008; 178(Preformulation in Solid Dosage Form Development):571-83
14. Ponnuswamy MN, Gromiha MM, Sony SM, Saraboji K. Conformational aspects and interaction studies of heterocyclic drugs. Topics in Heterocyclic Chemistry 2006;3(QSAR and Molecular Modeling Studies in Heterocyclic Drugs I):81-147
15. Edwards PJ, Sturino C Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists. Curr Med Chem 2011;18(20):3116-35
16. Cola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-16
17. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6(11):881-90 (Pubitemid 350042396)
18. Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18(17):4872-5
19. Keserue GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Revs Drug Discov 2009;8(3):203-12
20. Hann MM. Molecular obesity, potency and other addictions in drug discovery. Med Chem Commun 2011;2:349-55
21. Abad-Zapatero C Ligand efficiency indices for effective drug discovery. Expert Opin Drug Discov 2007;2(4):469-88 (Pubitemid 47073073)
22. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 2012;7(10):863-75
23. Walters PW. Going further than Lipinskis rule. Expert Opin Drug Discov 2012;7(2):99-107
24. Sonbol MB, Firwana B, et al. Comprehensive review of JAK kinase in myeloproliferative neoplasms. Ther Adv Hematol 2013;1):15-35
25. Reichetzeder C, Tsuprykov O, Hocher B. Endothelin receptor antagonists in clinical research - lessons learned from preclinical and clinical kidney studies. Life Sci 2014; Epub ahead of print
26. Hill AP, Young RJ. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug Discov Today 2010;15(15-16):648-55
27. Young RJ, Green DV, Luscombe CN, Hill AP. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today 2011;16(17-18):822-30
28. Medina-Franco J L. Interrogating novel areas of chemical space for drug discovery using chemoinformatics. Drug Dev Res 2012;73:430-8
29. Ruddigkeit L, van Deursen R, Blum LC, Reymond J-L. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J Chem Inf Model 2012;52:2864-75
30. Taylor RD, MacCoss M, Lawson AD. Rings in drugs. J Med Chem 2014; Epub ahead of print
31. Pitt WR, Parry DM, Perry BG, Groom CR. Heteroaromatic rings of the future. J Med Chem 2009;52:2952-63
32. Ritchie TJ, Luscombe CN, Macdonald SJ. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J Chem Inf Model 2009;49(4):1025-32